股票代码：301015 股票简称：百洋医药 债券代码：123194 债券简称：百洋转债 青岛百洋医药股份有限公司 投资者关系活动记录表 编号：IR2023-002 | --- | --- | --- | |--------------------|---------------|------------------------| | | □特定对象调研 | □分析师会议 | | | □媒体采访 | 业绩说明会 | | 投资者关系活动类别 | | | | | □新闻发布会 □ | 路演活动 | | | □现场参观 □ | 其他 | | 参与单位名称及人员 | 参与公司 2022 | 年度业绩说明会的投资者 | 时间 2023 年 6 月 7 日 参会方式 全景网"投资者关系互动平台"（https://ir.p5w.net） 董事长、总经理：付钢 上市公司接待人员姓名 财务总监、董事会秘书：王国强 独立董事：郝先经 公司就投资者在本次说明会中提出的问题进行了回复： 1、说一下公司新的增长点和公司在医药平台的优势？谢谢。 投资者您好，公司有四大驱动力保证业绩稳定增长，一是大品 牌战略，迪巧、泌特模式复制：商业化平台 ...

| 证券代码：301015 | 证券简称：百洋医药 公告编号：2023-041 | | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | 特此公告。 （问题征集专题页面二维码） 青岛百洋医药股份有限公司 董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛百洋医药股份有限公司定于 2023 年 6 月 7 日（星期三）15:00-16:30 在 全景网举办 2022 年度业绩说明会，本次年度业绩说明会将采用网络远程的方式 举行，投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本 次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼总经理付钢先生、财务总监兼董事 会秘书王国强先生、独立董事郝先经先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 6 月 6 日（星期二）15:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入 问题征集专题页面。公司 ...

Group 1: Company Overview and Performance - The company, Qingdao Baiyang Pharmaceutical Co., Ltd., reported significant brand signing breakthroughs in 2022, enhancing its brand operation capabilities recognized by upstream enterprises [2][3] - The company’s revenue from wholesale distribution has decreased, but this will not affect overall business growth as it focuses on optimizing its main brand operation business [3][4] Group 2: Brand Strategy and Market Demand - The company’s brand signing strategy is driven by market demand and its own capabilities, with a multi-brand matrix covering over 10 treatment areas [3] - The demand for calcium products is increasing due to rising health awareness and consumer spending on healthcare, with a notable growth in the imported calcium segment [3][4] Group 3: Product Development and Marketing - The company’s flagship product, the Dical series, is experiencing rapid growth due to targeted brand positioning and effective marketing strategies [3] - The company has established partnerships with major Japanese pharmaceutical companies to enhance its efficacy skincare product line, achieving revenue growth of 100% over the past two years [4] Group 4: Future Growth Drivers - Future growth is expected to be driven by a strong brand strategy, robust business development capabilities, expansion of proprietary brands, and innovative drug/device collaborations [4]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1.688 billion, a decrease of 9.35% year-on-year[4] - Net profit attributable to shareholders was CNY 122.41 million, an increase of 39.78% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 126.33 million, up 32.10% year-on-year[4] - The core brand operation business achieved revenue of CNY 917 million, a growth of 10.97% year-on-year[7] - The wholesale and distribution business reported revenue of CNY 677 million, a decline of 27.56% year-on-year[7] - The retail business generated revenue of CNY 86 million, down 8.57% year-on-year[7] - Total operating revenue for Q1 2023 was CNY 1,686,422,354.66, a decrease of 9.3% compared to CNY 1,860,324,319.90 in the same period last year[17] - Net profit for Q1 2023 was CNY 119,549,046.03, representing an increase of 38.7% from CNY 86,167,957.38 in Q1 2022[18] - Earnings per share (EPS) for Q1 2023 was CNY 0.2331, up from CNY 0.1668 in the previous year[19] Cash Flow and Assets - The net cash flow from operating activities was CNY 154.35 million, a significant increase of 219.87% year-on-year[4] - Cash flow from operating activities increased to CNY 1,934,367,869.47, compared to CNY 1,798,294,219.38 in the same period last year[20] - The net cash flow from operating activities for Q1 2023 was ¥154,352,220.05, compared to a negative cash flow of ¥128,761,948.04 in Q1 2022, indicating a significant improvement[21] - Total cash outflow from operating activities was ¥1,780,015,649.42, down from ¥1,927,056,167.42 in the same period last year[21] - The ending balance of cash and cash equivalents was ¥880,720,784.89, down from ¥1,069,897,263.74 at the end of Q1 2022[21] - The company's cash and cash equivalents reached CNY 1,145,973,401.21, up from CNY 1,047,765,015.27 at the beginning of the year, reflecting a growth of approximately 9.36%[14] - Accounts receivable decreased to CNY 1,844,001,727.03 from CNY 2,028,157,194.77, indicating a reduction of about 9.08%[14] - Inventory increased to CNY 734,246,491.68 from CNY 650,098,447.97, representing an increase of approximately 12.93%[15] Liabilities and Equity - The total current liabilities as of March 31, 2023, were CNY 2,538,325,243.19, a decrease from CNY 2,603,806,929.80 at the beginning of the year[15] - The company's total liabilities decreased to CNY 2,686,288,884.74 from CNY 2,750,922,581.18 year-on-year[18] - The total equity attributable to shareholders of the parent company increased to CNY 2,424,162,640.52, up from CNY 2,301,713,910.75 in the previous year[18] - The equity attributable to shareholders was CNY 2.424 billion, reflecting a growth of 5.32% year-on-year[4] Shareholder Information - The company had a total of 9,834 common shareholders at the end of the reporting period[8] - The top ten shareholders did not participate in margin trading or securities lending activities[12] Investments and Expenses - Research and development expenses for Q1 2023 were CNY 3,055,723.40, indicating ongoing investment in innovation[18] - The company reported a decrease in sales expenses to CNY 246,820,599.16 from CNY 286,178,225.72 year-on-year, reflecting cost control measures[18] - The company's long-term equity investments stood at CNY 181,024,756.70, slightly down from CNY 181,566,656.38[15] Regulatory and Agreements - The company signed a promotion agreement with Novartis Pharma Co., Ltd. in February 2023 to expand marketing activities for a designated product[13] - The company received approval from the China Securities Regulatory Commission for the issuance of convertible bonds on March 28, 2023[13] Other Financial Information - Other comprehensive income after tax was CNY -907,050.85, compared to CNY 38,308.91 in the previous year, indicating fluctuations in financial assets[19] - The report for Q1 2023 was not audited[22]

Dividend Distribution - The company plans to distribute a cash dividend of 7.62 CNY per 10 shares (before tax) to all shareholders, based on a total of 525,100,000 shares[3]. - The total distributable profit for 2022 is reported at 678,332,759.50 CNY, with the cash dividend accounting for 100% of the total profit distribution[146]. - The cash dividend distribution plan is subject to approval at the annual general meeting of shareholders[146]. Financial Performance - The company's operating revenue for 2022 was ¥7,509,618,040.76, representing a 6.50% increase compared to ¥7,051,567,224.86 in 2021[13]. - Net profit attributable to shareholders for 2022 was ¥502,089,121.05, a 19.08% increase from ¥421,641,693.50 in 2021[13]. - The net cash flow from operating activities for 2022 was ¥305,753,768.02, a significant increase of 68.65% compared to ¥181,296,527.31 in 2021[13]. - The company's total assets at the end of 2022 were ¥5,030,204,138.02, with net assets attributable to shareholders at ¥2,302,037,215.07, reflecting a 9.28% increase from the previous year[13]. - The company achieved a total revenue of 7.51 billion yuan in 2022, representing a year-on-year growth of 6.5%. Adjusted for the two-invoice system, revenue reached 8.65 billion yuan, a growth of 11.11%[33]. Risk Management - The company faces risks including brand operation concentration, drug quality, policy changes, and intensified market competition, which are detailed in the management discussion section[3]. - The company emphasizes the importance of risk awareness among investors regarding forward-looking statements and future plans[2]. - The company is proactive in monitoring policy changes to mitigate risks associated with regulatory impacts on the pharmaceutical industry[87]. Market Expansion and Strategy - The company reported a significant focus on new product development and market expansion strategies, although specific financial metrics were not disclosed in the provided content[3]. - The pharmaceutical brand operation industry in China is expected to grow from 472 billion RMB in 2019 to 1,390.3 billion RMB by 2023, with a CAGR of 25.1%[24]. - The company aims to provide comprehensive commercialization solutions for pharmaceutical manufacturers, covering brand operation, wholesale distribution, and retail[25]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region within the next two years[121]. Research and Development - Research and development (R&D) expenses reached CNY 3,315,890.90, marking a 100% increase compared to the previous year, reflecting investment in medical device development[57]. - The company expanded its R&D personnel to 30, with a composition of 43.33% holding master's degrees, indicating a focus on enhancing R&D capabilities[58]. - The R&D investment in new products and technologies has increased by 30%, totaling 150 million RMB, focusing on innovative healthcare solutions[126]. Corporate Governance - The company has established a governance structure in compliance with relevant laws and regulations, enhancing its internal control system[91]. - The company ensures the independence of its operations from its controlling shareholder, maintaining separate assets, personnel, and financial systems[99]. - The company has a total of 9 board members, including 3 independent directors, ensuring a reasonable professional structure[94]. Investor Relations - The company emphasizes the importance of investor relations, providing multiple channels for communication and ensuring timely information disclosure[98]. - The company conducted investor relations activities from May 5 to May 17, 2022, discussing the 2021 annual and Q1 2022 operational performance with 20 institutions[90]. - The first extraordinary general meeting of 2022 had an investor participation rate of 80.90%[106]. Compliance and Transparency - The company is committed to ensuring the accuracy and completeness of its financial reports, as stated by its management team[2]. - The company reported a commitment to compensate investors for losses incurred due to any false statements or omissions in the prospectus, in accordance with applicable laws and regulations[178]. - The company has committed to transparency and accountability, stating that any failure to fulfill public commitments will result in new commitments and potential penalties for responsible executives[183]. Social Responsibility - The company actively participates in public welfare activities, including donations to various foundations for children's health and sports development[155]. - The company donated a total of 2 million RMB to the Chinese Medical Association for the "Chinese Physician Award" during the reporting period[155]. - The company has actively responded to national poverty alleviation initiatives by providing medical aid and resources[156]. Employee Management - The total number of employees at the end of the reporting period was 2,642, with 1,762 in the parent company and 880 in major subsidiaries[141]. - The company implemented a competitive salary management system, linking compensation closely to performance and company profitability[142]. - The company established a comprehensive employee training program to enhance personal and professional development, integrating training with strategic goals[143].

青岛百洋医药股份有限公司 2022 年第三季度报告 证券代码：301015 证券简称：百洋医药 公告编号：2022-065 青岛百洋医药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 青岛百洋医药股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 同一控制下企业合并 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------|--- ...

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥3.73 billion, representing an increase of 11.50% compared to the same period last year [22]. - The net profit attributable to shareholders was approximately ¥214.80 million, reflecting a growth of 14.58% year-over-year [22]. - The net cash flow from operating activities improved significantly to approximately ¥111.82 million, a 637.02% increase from the previous year [22]. - The company's total assets at the end of the reporting period were approximately ¥4.55 billion, a decrease of 1.13% from the end of the previous year [22]. - The net assets attributable to shareholders decreased by 6.55% to approximately ¥2.02 billion compared to the end of the previous year [22]. - The company's gross profit margin for the brand operation business was 47.00%, while the wholesale distribution business had a gross profit margin of 9.44% [62]. - The company reported a total revenue of 1,152.26 million yuan for the reporting period [121]. - The company reported a net profit of 500 million for the first half of 2022, a 50% increase compared to the same period last year [136]. - The total revenue for the first half of 2022 was approximately 1.79 billion yuan, representing a year-on-year increase of 7.9% [192]. - The net profit attributable to shareholders was approximately 350 million yuan, with a profit distribution of 1.7 million yuan to shareholders [193]. Business Operations - The company operates in the pharmaceutical distribution industry, focusing on brand operation and commercialization of high-quality pharmaceutical products [30]. - The company aims to provide comprehensive commercialization solutions for pharmaceutical manufacturers, including brand operation, wholesale distribution, and retail services [32]. - The company has established a comprehensive commercial solution for pharmaceutical products, covering brand operation, wholesale distribution, and retail services [39]. - The company has expanded its brand operation capabilities, collaborating with major pharmaceutical companies and establishing a multi-brand matrix covering over 10 therapeutic areas [34]. - The company has developed a modern logistics distribution information monitoring process to ensure safe and efficient delivery of pharmaceutical products [36]. - The company has significantly increased the number of brands operated since 2015, enhancing its core competitiveness and overall revenue scale [46]. - The company has established a national pharmaceutical commercial network with over 600 distributors, covering more than 10,000 hospitals and 370,000 pharmacies [55]. - The company is focusing on deep market penetration and product combination marketing strategies to meet diverse customer needs [45]. Risk Management - The company faces risks including brand operation concentration, drug quality, policy changes, and intensified market competition [4]. - The management emphasizes the importance of risk awareness regarding forward-looking statements made in the report [4]. - The company has implemented strict quality management measures across all stages of drug handling to mitigate drug quality risks [95]. - The company is actively monitoring policy changes in the medical industry to adapt its business strategies accordingly, reducing potential policy risks [96]. - The competitive landscape in the pharmaceutical industry is intensifying, prompting the company to enhance its brand operation capabilities and expand its marketing network [97]. Corporate Governance - The financial report is guaranteed to be true, accurate, and complete by the company's management, including the chairman and accounting head [4]. - The company has established a comprehensive corporate governance structure and internal control system to ensure compliance with regulations [109]. - There were no changes in the company's board of directors or senior management during the reporting period [104]. - The company has fulfilled its share lock-up commitments as per the regulations [115]. - The company is in compliance with all regulatory requirements regarding share transfers and management [114]. Shareholder Information - The company reported a related party transaction amounting to 15.77 million yuan, which represents 5.85% of similar transactions [122]. - The largest shareholder, Baiyang Pharmaceutical Group, holds 70.29% of the shares, totaling 369,077,400 shares, with no changes during the reporting period [154]. - The total number of restricted shares decreased from 477,760,000 to 406,725,000, representing a reduction of 71,035,000 shares [148]. - The total number of unrestricted shares increased from 47,340,000 to 118,375,000, representing an increase of 71,035,000 shares [148]. - The company has not reported any share buybacks or significant changes in shareholding structure during the reporting period [153]. Future Outlook - The company provided a future outlook with a revenue guidance of 4,500 million for the full year 2022, representing a 25% increase from 2021 [135]. - The company plans to focus on expanding its market presence and developing new products to drive future growth [186]. - Future guidance indicates an expected revenue growth rate of around 10% for the next half of the year, driven by new product launches [192]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings [195]. Social Responsibility - The company emphasizes its commitment to corporate social responsibility and maintaining good relationships with suppliers and customers [109]. - The company donated a total of 1.1 million yuan to various charitable causes during the reporting period [110].

Financial Performance - The company's operating revenue for 2021 was ¥7,051,567,224.86, representing a 19.94% increase compared to ¥5,879,322,863.17 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥422,805,909.30, a 55.04% increase from ¥272,710,844.25 in 2020[18]. - The net cash flow from operating activities improved significantly to ¥183,556,969.07, compared to a negative cash flow of ¥116,834,538.03 in 2020, marking a 257.11% increase[18]. - The basic earnings per share for 2021 was ¥0.85, up 46.55% from ¥0.58 in 2020[18]. - The total assets at the end of 2021 were ¥4,598,027,462.95, a 14.93% increase from ¥4,000,862,159.07 at the end of 2020[18]. - The company's net assets attributable to shareholders increased by 46.50% to ¥2,156,343,070.03 at the end of 2021, compared to ¥1,471,896,330.01 at the end of 2020[18]. - The total revenue for 2021 was significantly impacted by the increase in sales, with the top five customers contributing a total sales amount of ¥1,670,905,365.44, accounting for 23.70% of the annual sales[75]. - The company reported a net profit margin of 12% for 2021, an increase from 10% in 2020, indicating improved operational efficiency[165]. Revenue Breakdown - Sales from pharmaceuticals and medical devices accounted for ¥6,525,086,315.08, which is 92.54% of total revenue, with a year-on-year growth of 19.64%[66]. - The brand service segment generated ¥504,481,753.00, contributing 7.15% to total revenue, and saw a growth of 22.93% compared to the previous year[66]. - The core brand operation business generated revenue of 2.905 billion yuan, up 34.11%; adjusted for the two-invoice system, revenue was 3.641 billion yuan, a 52.21% increase[45]. - The wholesale and distribution business reported revenue of 3.706 billion yuan, a year-on-year increase of 9.94%[48]. - Retail business revenue reached 419 million yuan, reflecting a growth of 27.93%[49]. - The company launched the new Hai Lu brand, generating revenue of 298 million yuan, establishing it as a leading retail eye drop brand[46]. Market Expansion and Strategy - The company aims to become a leading commercial platform for health brands, focusing on marketing comprehensive services for pharmaceutical manufacturers[35]. - The company is focusing on professional sales promotion platforms as a key component of the pharmaceutical industry, driven by increasing market competition and the need for specialized services[29]. - The company plans to continue its market expansion and product development strategies, focusing on enhancing management and operational efficiency[85]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, with a budget of 200 million RMB allocated for this purpose[136]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[158]. Risk Management - The company faces risks including brand operation concentration, drug quality, policy changes, and intensified market competition, which are detailed in the management discussion and analysis section[4]. - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[4]. - The company has established a strict quality management system to mitigate drug quality risks, ensuring control over the entire process from procurement to sales[110]. - The company is focused on proactive measures to adapt to regulatory changes in the medical industry, aiming to minimize operational risks associated with policy shifts[112]. Corporate Governance - The company has established a comprehensive corporate governance structure and internal control system to ensure compliance with information disclosure obligations[193]. - The board of directors consists of 11 members, including 4 independent directors, ensuring compliance with legal requirements and a reasonable professional structure[121]. - The company has independent financial departments and systems, allowing for independent financial decision-making and tax obligations[129]. - The company has established independent operational departments that function effectively without subordination to the controlling shareholders[130]. Research and Development - The company is investing 50 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[136]. - Investment in R&D increased by 30%, focusing on innovative healthcare solutions and technology advancements[158]. - The company has a strategy to enhance its product offerings through ongoing research and development initiatives[162]. Shareholder Engagement - The company reported a profit distribution plan of 6.67 CNY per 10 shares (including tax) for all shareholders, based on a total share capital of 525,100,000 shares[4]. - The total distributable profit for the year was 925,665,917.92 CNY, with the cash dividend representing 100% of the profit distribution[180]. - The company has a well-defined strategy for investor communication to protect shareholders' rights and interests[193]. Social Responsibility - The company actively participates in public welfare activities, demonstrating its commitment to corporate social responsibility[194]. - The company donated a total of 2 million RMB to various charitable organizations, including 2 million RMB to Tsinghua University and 1.5 million RMB to UNICEF for sports development projects in China[194]. - The management team emphasized a commitment to sustainability and corporate social responsibility initiatives, aiming to reduce carbon emissions by 30% by 2025[136].

青岛百洋医药股份有限公司 2022 年第一季度报告全文 1 证券代码：301015 证券简称：百洋医药 公告编号：2022-026 青岛百洋医药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性 陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、 准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | | 本报告 ...

青岛百洋医药股份有限公司 2021 年第三季度报告 证券代码：301015 证券简称：百洋医药 公告编号：2021-016 青岛百洋医药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|-------------------------- ...